Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Iovance Biotherapeutics, Inc.    IOVA

IOVANCE BIOTHERAPEUTICS, INC.

(IOVA)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/07/2019 11/08/2019 11/11/2019 11/12/2019 11/13/2019 Date
20.66(c) 23.62(c) 23.87(c) 22.9(c) 22.62(c) Last
1 150 090 2 840 032 1 794 960 1 359 590 815 116 Volume
-2.78% +14.33% +1.06% -4.06% -1.22% Change
More quotes
Financials (USD)
Sales 2019 -
EBIT 2019 -196 M
Net income 2019 -187 M
Finance 2019 318 M
Yield 2019 -
Sales 2020 21,4 M
EBIT 2020 -223 M
Net income 2020 -244 M
Finance 2020 342 M
Yield 2020 -
P/E ratio 2019 -15,1x
P/E ratio 2020 -13,7x
EV / Sales2019 -
EV / Sales2020 117x
Capitalization 2 855 M
More Financials
Company
Iovance Biotherapeutics, Inc., formerly Lion Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer... 
Sector
Biotechnology & Medical Research
Calendar
11/12 | 06:45pmPresentation
More about the company
Surperformance© ratings of Iovance Biotherapeutics, I
Trading Rating : Investor Rating : -
More Ratings
Latest news on IOVANCE BIOTHERAPEUTICS, I
11/12IOVANCE BIOTHERAPEUTICS : Lytix Biopharma is featured in Finansavisen, talking a..
AQ
11/11IOVANCE BIOTHERAPEUTICS : Announces Updated Phase 2 Clinical Data from the Lifil..
AQ
11/11LYTIX BIOPHARMA ANNOUNCES A CLINICAL : Iova)
AQ
11/08Iovance Biotherapeutics Announces Updated Phase 2 Clinical Data from the Lifi..
GL
11/07Iovance Biotherapeutics to Present at Upcoming Investor Conferences in Novemb..
GL
11/04IOVANCE BIOTHERAPEUTICS : Management's Discussion and Analysis of Financial Cond..
AQ
11/04IOVANCE BIOTHERAPEUTICS : 3Q Earnings Snapshot
AQ
11/04IOVANCE BIOTHERAPEUTICS, INC. : Results of Operations and Financial Condition, F..
AQ
11/04Iovance Biotherapeutics Reports Third Quarter and September Year-to-Date 2019..
GL
10/31Iovance Biotherapeutics to Host Third Quarter 2019 Financial Results Conferen..
GL
10/02Iovance Biotherapeutics Announces Four Abstracts to be Presented at the Upcom..
GL
09/30IOVANCE BIOTHERAPEUTICS : to Present at Upcoming Conferences
AQ
09/27Iovance Biotherapeutics to Present at Upcoming Conferences
GL
08/26Iovance Biotherapeutics to Present at Upcoming Investor Conferences in Septem..
GL
08/01IOVANCE BIOTHERAPEUTICS : 2Q Earnings Snapshot
AQ
More news
News in other languages on IOVANCE BIOTHERAPEUTICS, I

- No features available -

More news
Sector news : Bio Diagnostics & Testing
11/07GILEAD SCIENCES : U.S. Sues HIV Drugmaker Gilead Alleging It Infringed on PrEP P..
DJ
11/07GILEAD SCIENCES : U.S. Sues HIV Drugmaker Gilead Alleging It Infringed on PrEP P..
DJ
11/06Biogen Adding Ophthalmology Biosimilars in Deal With Samsung Bioepis
DJ
11/06CELLTRION : 3Q Net Profit Rose 13% on Year
DJ
11/05Regeneron Pharmaceuticals Up Over 9%, on Pace for Largest Percent Increase Si..
DJ
More sector news : Bio Diagnostics & Testing
Chart IOVANCE BIOTHERAPEUTICS, INC.
Duration : Period :
Iovance Biotherapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IOVANCE BIOTHERAPEUTICS, I
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Average target price 34,88  $
Last Close Price 22,62  $
Spread / Highest target 165%
Spread / Average Target 54,2%
Spread / Lowest Target 32,6%
EPS Revisions
Managers
NameTitle
Maria Fardis President, Chief Executive Officer & Director
Iain D. Dukes Chairman
Timothy E. Morris Secretary, Chief Financial & Accounting Officer
Friedrich Graf Finckenstein Chief Medical Officer
Merrill A. McPeak Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
IOVANCE BIOTHERAPEUTICS, INC.155.59%2 855
GUARDANT HEALTH, INC.95.69%6 010
GENSCRIPT BIOTECH CORPORATION72.38%4 764
INVITAE CORPORATION55.88%1 509
MIRACA HOLDINGS INC.8.80%1 389
VERACYTE, INC.91.81%1 163